Page 489 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

16. ANTHRACYCLINES : PERSPECTIVES 447

PRIEBE W. et al., Bis-anthracyclines with high activity against doxorubicin resistant
tumors, U. S. Patent 5, 874, 412, Feb. 23, 1999.
QU X., CHAIRES J. B., Contrasting hydration changes for ethidium and daunomycin
binding to DNA. J. Am. Chem. Soc., 1999, 121, 2649-2650.
TAATJES D. J., KOCH T. H., Growth inhibition, nuclear uptake and retention of anthra-
cycline-formaldehyde conjugates in prostate cancer cells relative to clinical anthracy-
clines, Anticancer Res., 1999, 19, 1201-1208.
TAATJES, D. J. et al., Nuclear targeting and nuclear retention of anthracycline-formalde-
hyde conjugates implicate DNA covalent bonding in the cytotoxic mechanism of
anthracyclines, Chem. Res. Toxicol., 1999, 12, 588-596.
WULFF W. D. et al., Studies toward the synthesis of Menogaril : synthesis of a-ring pre-
cursors and their conversion to the tetracyclic core via the benzannulation reaction,
Synthesis, 1999, 3, 415-422.
BIGIONI M. et al., Influence of sugar modification on antitumor activity in a new series of
disaccharide anthracyclines, communication poster, 2000 NCl•EORTC•AACR Sym-
posium, Clin. Cancer Res., 2000, 6, 4538s.
BOOSER D. J. et al., Phase I study of liposomal annamycin, Cancer Chemother. Phar-
macol., 2000, 46, 427-432.
GERONI et al., Synergistic combinations of PNU-159548 with other antitumor drugs,
Proceedings of the 11th NCIEORTC.AACR Symposium, November 2000,poster 364.
GERONI C. et al., Pharmacological and toxicological aspects of 4-demethoxy-3'-dea-
mino-3'-aziridinyl-4'-méthylsulphonyl-daunorubicin (PNU-159548): a novel antineo-
plastic agent, Cancer Res., 2001, 61, 1983-1990.
PRATESI G., MONESTIROLI S. V., Preclinical evaluation of new anthracyclines, Current
Med. Chem., 2001, 8, 9-13.